Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Hepatitis: Drugs

Department of Health written question – answered on 7th June 2016.

Alert me about debates like this

Photo of Baroness Randerson Baroness Randerson Liberal Democrat Lords Spokesperson (Transport)

To ask Her Majesty’s Government why NHS England has decided to restrict hepatitis C treatment, with providers subject to a financial penalty if they do not keep within specified numbers, despite those treatments being approved as cost-effective by NICE.

Photo of Lord Prior of Brampton Lord Prior of Brampton The Parliamentary Under-Secretary of State, Department of Health

The National Institute for Health and Care Excellence (NICE) specifically requires Operational Delivery Networks (ODNs) to prioritise hepatitis C patients on the basis of highest unmet clinical need, as part of a progressive rollout of treatments over the next five years.

NHS England is funding providers to treat patients at the rate outlined in NICE’s guidance, Technology Appraisals 363, 364 and 365, apportioned to local ODNs based on local health needs. Copies of these Technology Appraisals are attached.

NICE Technology Appraisal 364 (PDF Document, 239.39 KB)
NICE Technology Appraisal 365 (PDF Document, 206.24 KB)

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.